Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jun 6;11:5243–5254. doi: 10.2147/CMAR.S196355

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Chen et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

ELF-1 targeted the CCL2 promoter region and activated CCL2/CCR2 signaling. (A) The ELF-1 target site in the promoter region of CCL2 was presented. Endogenous ELF-1 binding to the CCL2 promoter was assessed using ChIP assay. (B and C) A luciferase assay was used to detect the transcription of CCL2 in ELF-1-overexpressing transfectants or siELF-1 transfectants in a dose-dependent manner. (D and E) mRNA expression levels of survivin and VEGF-A were determined in overexpressing-ELF-1 and siELF-1 NPC cells by Q-RT-PCR. *p<0.05; **p<0.01; ***p<0.001.

Abbreviations: CCL2, C-C motif chemokine ligand 2; CCR2, C-C chemokine receptor 2; ChIP, Chromatin immunoprecipitation; MTT, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NPC, nasopharyngeal carcinoma.